Welcome to our dedicated page for Arrivent Biopharma SEC filings (Ticker: AVBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ArriVent BioPharma, Inc. (AVBP) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. ArriVent is a Nasdaq-listed, clinical-stage biopharmaceutical company, and its filings offer insight into the development of firmonertinib and its antibody-drug conjugate pipeline, as well as its capital structure and governance.
Through current reports on Form 8-K, ArriVent reports material events such as quarterly financial results, interim and final clinical data updates for firmonertinib in EGFR exon 20 insertion and PACC mutant non-small cell lung cancer (NSCLC), public offerings of common stock and pre-funded warrants, and collaboration agreements. These filings also confirm that ArriVent’s common stock trades on The Nasdaq Stock Market LLC under the symbol AVBP and identify the company as an emerging growth company.
Investors can use this page to review how ArriVent describes its pivotal Phase 3 trials like FURVENT and ALPACCA, its Phase 1b FURTHER study, and regulatory milestones such as FDA Breakthrough Therapy Designation and Orphan Drug Designation for firmonertinib. Filings may also discuss pipeline assets such as ARR-217 (MRG007), a CDH17-targeted ADC, and outline how equity offerings and cash resources are intended to support ongoing research and development.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify information on clinical trial status, financial condition, and corporate actions. Real-time updates from EDGAR, along with structured access to 8-Ks and other core filings, allow users to monitor changes in ArriVent’s development programs, financing activities, and governance without manually parsing every page.
ArriVent BioPharma (Nasdaq: AVBP) furnished an 8-K to disclose positive interim results from its global Phase 1b FURTHER study evaluating first-line firmonertinib monotherapy in patients with EGFR P-loop and α-C-helix compressing (PACC) mutant non-small cell lung cancer (NSCLC).
At the 240 mg dose, investigators observed a median progression-free survival (mPFS) of 16.0 months and a median duration of response of 14.6 months (cut-off 3 Mar 2025). Tumor shrinkage of ≥30%—the study’s threshold for overall response—occurred in 68.2% of first-line patients at 240 mg versus 43.5% at 160 mg. Among patients presenting with brain metastases, 41% achieved a confirmed response and 53% recorded ≥30% tumor reduction, underscoring central-nervous-system activity.
Safety remained favorable: no Grade 4 or 5 treatment-related adverse events (TRAEs) and no treatment discontinuations; the most common TRAEs were diarrhea, elevated hepatic enzymes, rash, stomatitis and dry skin.
Based on these data, AVBP will launch ALPACCA (FURMO-006), a randomized global Phase 3 trial using the 240 mg dose, with first-patient-in targeted for the second half of 2025. The press release detailing the findings is furnished as Exhibit 99.1; information under Item 7.01 is not deemed “filed” for Exchange Act purposes.
ArriVent BioPharma (NASDAQ:AVBP) submitted a routine Form 4 on 28 June 2025 reporting an insider transaction by director Merdad Parsey.
According to the filing, Parsey acquired 15,502 non-qualified stock options on 18 June 2025 at an exercise price of $24.89 per share. The options become exercisable on 18 June 2026 and expire on 17 June 2035. No common shares were sold or purchased outright, and the transaction was reported as direct ownership. After the grant, Parsey holds an additional 15,502 derivative securities linked to AVBP common stock.
No other material changes, sales, or new share ownership percentages were disclosed in this filing.
Form 4 filing reveals that Kristine Peterson, Director at ArriVent BioPharma, was granted 15,502 non-qualified stock options on June 18, 2025. The options have the following key terms:
- Exercise price set at $24.89 per share
- Exercisable starting June 18, 2026
- Expiration date of June 17, 2035
- Underlying security is ArriVent BioPharma common stock
The options were acquired at a price of $0.00, indicating a compensation grant. The filing was signed by James Kastenmayer as attorney-in-fact for Peterson on June 20, 2025. This equity compensation aligns the director's interests with shareholders through long-term stock ownership potential.
ArriVent BioPharma director John Hohneker received a non-qualified stock option grant on June 18, 2025. The key details of this insider transaction include:
- Granted 15,502 stock options to purchase common stock
- Exercise price set at $24.89 per share
- Options become exercisable on June 18, 2026
- Options expire on June 17, 2035
- Total cost basis of $0.00 as this was a compensation grant
The transaction was reported via Form 4 filing and executed through attorney-in-fact James Kastenmayer. This equity-based compensation aligns the director's interests with shareholders and represents a standard component of non-employee director compensation.
ArriVent BioPharma director Chris Nolet received a new stock option grant on June 18, 2025. The transaction details include:
- Granted 15,502 non-qualified stock options to purchase common stock
- Exercise price set at $24.89 per share
- Options become exercisable on June 18, 2026
- Options expire on June 17, 2035
- Zero cost basis for the options grant
This Form 4 filing, signed by James Kastenmayer as attorney-in-fact, represents a standard director compensation equity grant. The options provide Nolet with long-term alignment with shareholder interests through a 10-year exercise window, subject to a one-year vesting requirement.